Torrent Pharma introduces Molnupiravir under the brand name Molnutor® in India

Torrent Pharma has today announced that it is introducing MSD (a trade name of Merck & Co., Inc, Kenilworth, NJ, USA) and Ridgeback's molnupiravir under the brand name Molnutor® in India. Earlier this year, Torrent Pharma inked a non-exclusive voluntary licensing pact with MSD, granting rights to Torrent Pharma for manufacturing, distribution and marketing of Molnupiravir in more than 100 low-and middle income markets including India for treatment of COVID-19.

The Drugs Controller General of India (DCGI), based on the review of clinical data of Molnupiravir has approved the drug for the treatment of COVID-19 in adults for restricted emergency use in India.

Molnupiravir is the oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and U.S. Food and Drug Administration (FDA) [for Emergency Use Authorisation (EUA)] for the treatment of mild-to-moderate COVID-19 in adults.

Shares of Torrent Pharmaceuticals Limited was last trading in BSE at Rs. 3148.95 as compared to the previous close of Rs. 3044.95. The total number of shares traded during the day was 10090 in over 1727 trades.

The stock hit an intraday high of Rs. 3159.70 and intraday low of 3040.25. The net turnover during the day was Rs. 31579109.00.

Source : Equity Bulls

Keywords

TorrentPharmaceuticals INE685A01028 TORNTPHARM Molnupiravir Molnutor Covid19Treatment